English
简体中文
Total: £ 56.28
Published Date: 2026-02-03 | Pages: 102 | Tables: 102 | Medical Care
The global Systemic Autoinflammatory Diseases Drug market was valued at US$ 14940 million in 2025 and is anticipated to reach US$ 20380 million by 2032, at a CAGR of 4.6% from 2026 to 2032.
Systemic autoinflammatory disease drugs are medications used to treat a group of conditions characterized by inappropriate and chronic activation of the body’s innate immune system, leading to widespread inflammation in various organs. Unlike autoimmune diseases, which are driven by the adaptive immune system attacking self-antigens, autoinflammatory diseases originate from innate immune dysregulation. Common conditions include familial Mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), and systemic juvenile idiopathic arthritis (sJIA). These drugs, often targeting inflammatory pathways, aim to control flare-ups, reduce inflammation, and prevent long-term organ damage.
The North American market for Systemic Autoinflammatory Diseases Drug is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Systemic Autoinflammatory Diseases Drug is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Systemic Autoinflammatory Diseases Drug in Ulcerative Colitis is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Systemic Autoinflammatory Diseases Drug include Novartis, Abbvie, Abbott Laboratories, Regeneron Pharmaceuticals, Swedish Orphan Biovitrum AB, Pfizer, Inc., Bausch Health, Mallinckrodt, Johnson & Johnson, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Systemic Autoinflammatory Diseases Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Systemic Autoinflammatory Diseases Drug. The Systemic Autoinflammatory Diseases Drug market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Systemic Autoinflammatory Diseases Drug market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Systemic Autoinflammatory Diseases Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Novartis
Abbvie
Abbott Laboratories
Regeneron Pharmaceuticals
Swedish Orphan Biovitrum AB
Pfizer, Inc.
Bausch Health
Mallinckrodt
Johnson & Johnson
Segment by Type
Injectables
Oral
Other
Segment by Application
Ulcerative Colitis
Juvenile Rheumatoid Arthritis
Psoriatic Arthritis
Other Indications
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Systemic Autoinflammatory Diseases Drug companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Systemic Autoinflammatory Diseases Drug Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Injectables
1.2.3 Oral
1.2.4 Other
1.3 Market by Application
1.3.1 Global Systemic Autoinflammatory Diseases Drug Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Ulcerative Colitis
1.3.3 Juvenile Rheumatoid Arthritis
1.3.4 Psoriatic Arthritis
1.3.5 Other Indications
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Systemic Autoinflammatory Diseases Drug Market Perspective (2021–2032)
2.2 Global Systemic Autoinflammatory Diseases Drug Growth Trends by Region
2.2.1 Global Systemic Autoinflammatory Diseases Drug Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Systemic Autoinflammatory Diseases Drug Historic Market Size by Region (2021–2026)
2.2.3 Systemic Autoinflammatory Diseases Drug Forecasted Market Size by Region (2027–2032)
2.3 Systemic Autoinflammatory Diseases Drug Market Dynamics
2.3.1 Systemic Autoinflammatory Diseases Drug Industry Trends
2.3.2 Systemic Autoinflammatory Diseases Drug Market Drivers
2.3.3 Systemic Autoinflammatory Diseases Drug Market Challenges
2.3.4 Systemic Autoinflammatory Diseases Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Systemic Autoinflammatory Diseases Drug Players by Revenue
3.1.1 Global Top Systemic Autoinflammatory Diseases Drug Players by Revenue (2021–2026)
3.1.2 Global Systemic Autoinflammatory Diseases Drug Revenue Market Share by Players (2021–2026)
3.2 Global Top Systemic Autoinflammatory Diseases Drug Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Systemic Autoinflammatory Diseases Drug Revenue
3.4 Global Systemic Autoinflammatory Diseases Drug Market Concentration Ratio
3.4.1 Global Systemic Autoinflammatory Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Systemic Autoinflammatory Diseases Drug Revenue in 2025
3.5 Global Key Players of Systemic Autoinflammatory Diseases Drug Head Offices and Areas Served
3.6 Global Key Players of Systemic Autoinflammatory Diseases Drug, Products and Applications
3.7 Global Key Players of Systemic Autoinflammatory Diseases Drug, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Systemic Autoinflammatory Diseases Drug Breakdown Data by Type
4.1 Global Systemic Autoinflammatory Diseases Drug Historic Market Size by Type (2021–2026)
4.2 Global Systemic Autoinflammatory Diseases Drug Forecasted Market Size by Type (2027–2032)
5 Systemic Autoinflammatory Diseases Drug Breakdown Data by Application
5.1 Global Systemic Autoinflammatory Diseases Drug Historic Market Size by Application (2021–2026)
5.2 Global Systemic Autoinflammatory Diseases Drug Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Systemic Autoinflammatory Diseases Drug Market Size (2021–2032)
6.2 North America Systemic Autoinflammatory Diseases Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Systemic Autoinflammatory Diseases Drug Market Size by Country (2021–2026)
6.4 North America Systemic Autoinflammatory Diseases Drug Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Systemic Autoinflammatory Diseases Drug Market Size (2021–2032)
7.2 Europe Systemic Autoinflammatory Diseases Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Systemic Autoinflammatory Diseases Drug Market Size by Country (2021–2026)
7.4 Europe Systemic Autoinflammatory Diseases Drug Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Systemic Autoinflammatory Diseases Drug Market Size (2021–2032)
8.2 Asia-Pacific Systemic Autoinflammatory Diseases Drug Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Systemic Autoinflammatory Diseases Drug Market Size by Region (2021–2026)
8.4 Asia-Pacific Systemic Autoinflammatory Diseases Drug Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Systemic Autoinflammatory Diseases Drug Market Size (2021–2032)
9.2 Latin America Systemic Autoinflammatory Diseases Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Systemic Autoinflammatory Diseases Drug Market Size by Country (2021–2026)
9.4 Latin America Systemic Autoinflammatory Diseases Drug Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Systemic Autoinflammatory Diseases Drug Market Size (2021–2032)
10.2 Middle East & Africa Systemic Autoinflammatory Diseases Drug Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Systemic Autoinflammatory Diseases Drug Market Size by Country (2021–2026)
10.4 Middle East & Africa Systemic Autoinflammatory Diseases Drug Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Systemic Autoinflammatory Diseases Drug Introduction
11.1.4 Novartis Revenue in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
11.1.5 Novartis Recent Development
11.2 Abbvie
11.2.1 Abbvie Company Details
11.2.2 Abbvie Business Overview
11.2.3 Abbvie Systemic Autoinflammatory Diseases Drug Introduction
11.2.4 Abbvie Revenue in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
11.2.5 Abbvie Recent Development
11.3 Abbott Laboratories
11.3.1 Abbott Laboratories Company Details
11.3.2 Abbott Laboratories Business Overview
11.3.3 Abbott Laboratories Systemic Autoinflammatory Diseases Drug Introduction
11.3.4 Abbott Laboratories Revenue in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
11.3.5 Abbott Laboratories Recent Development
11.4 Regeneron Pharmaceuticals
11.4.1 Regeneron Pharmaceuticals Company Details
11.4.2 Regeneron Pharmaceuticals Business Overview
11.4.3 Regeneron Pharmaceuticals Systemic Autoinflammatory Diseases Drug Introduction
11.4.4 Regeneron Pharmaceuticals Revenue in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
11.4.5 Regeneron Pharmaceuticals Recent Development
11.5 Swedish Orphan Biovitrum AB
11.5.1 Swedish Orphan Biovitrum AB Company Details
11.5.2 Swedish Orphan Biovitrum AB Business Overview
11.5.3 Swedish Orphan Biovitrum AB Systemic Autoinflammatory Diseases Drug Introduction
11.5.4 Swedish Orphan Biovitrum AB Revenue in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
11.5.5 Swedish Orphan Biovitrum AB Recent Development
11.6 Pfizer, Inc.
11.6.1 Pfizer, Inc. Company Details
11.6.2 Pfizer, Inc. Business Overview
11.6.3 Pfizer, Inc. Systemic Autoinflammatory Diseases Drug Introduction
11.6.4 Pfizer, Inc. Revenue in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
11.6.5 Pfizer, Inc. Recent Development
11.7 Bausch Health
11.7.1 Bausch Health Company Details
11.7.2 Bausch Health Business Overview
11.7.3 Bausch Health Systemic Autoinflammatory Diseases Drug Introduction
11.7.4 Bausch Health Revenue in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
11.7.5 Bausch Health Recent Development
11.8 Mallinckrodt
11.8.1 Mallinckrodt Company Details
11.8.2 Mallinckrodt Business Overview
11.8.3 Mallinckrodt Systemic Autoinflammatory Diseases Drug Introduction
11.8.4 Mallinckrodt Revenue in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
11.8.5 Mallinckrodt Recent Development
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Details
11.9.2 Johnson & Johnson Business Overview
11.9.3 Johnson & Johnson Systemic Autoinflammatory Diseases Drug Introduction
11.9.4 Johnson & Johnson Revenue in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
11.9.5 Johnson & Johnson Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Systemic Autoinflammatory Diseases Drug Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Injectables
Table 3. Key Players of Oral
Table 4. Key Players of Other
Table 5. Global Systemic Autoinflammatory Diseases Drug Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Systemic Autoinflammatory Diseases Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Systemic Autoinflammatory Diseases Drug Market Size by Region (US$ Million), 2021–2026
Table 8. Global Systemic Autoinflammatory Diseases Drug Market Share by Region (2021–2026)
Table 9. Global Systemic Autoinflammatory Diseases Drug Forecasted Market Size by Region (US$ Million), 2027–2032
Table 10. Global Systemic Autoinflammatory Diseases Drug Market Share by Region (2027–2032)
Table 11. Systemic Autoinflammatory Diseases Drug Market Trends
Table 12. Systemic Autoinflammatory Diseases Drug Market Drivers
Table 13. Systemic Autoinflammatory Diseases Drug Market Challenges
Table 14. Systemic Autoinflammatory Diseases Drug Market Restraints
Table 15. Global Systemic Autoinflammatory Diseases Drug Revenue by Players (US$ Million), 2021–2026
Table 16. Global Systemic Autoinflammatory Diseases Drug Market Share by Players (2021–2026)
Table 17. Global Top Systemic Autoinflammatory Diseases Drug Players by Tier (Tier 1, Tier 2, and Tier 3), based on Systemic Autoinflammatory Diseases Drug Revenue, 2025
Table 18. Ranking of Global Top Systemic Autoinflammatory Diseases Drug Companies by Revenue (US$ Million) in 2025
Table 19. Global 5 Largest Players Market Share by Systemic Autoinflammatory Diseases Drug Revenue (CR5 and HHI), 2021–2026
Table 20. Global Key Players of Systemic Autoinflammatory Diseases Drug, Headquarters and Area Served
Table 21. Global Key Players of Systemic Autoinflammatory Diseases Drug, Products and Applications
Table 22. Global Key Players of Systemic Autoinflammatory Diseases Drug, Date of General Availability (GA)
Table 23. Mergers and Acquisitions, Expansion Plans
Table 24. Global Systemic Autoinflammatory Diseases Drug Market Size by Type (US$ Million), 2021–2026
Table 25. Global Systemic Autoinflammatory Diseases Drug Revenue Market Share by Type (2021–2026)
Table 26. Global Systemic Autoinflammatory Diseases Drug Forecasted Market Size by Type (US$ Million), 2027–2032
Table 27. Global Systemic Autoinflammatory Diseases Drug Revenue Market Share by Type (2027–2032)
Table 28. Global Systemic Autoinflammatory Diseases Drug Market Size by Application (US$ Million), 2021–2026
Table 29. Global Systemic Autoinflammatory Diseases Drug Revenue Market Share by Application (2021–2026)
Table 30. Global Systemic Autoinflammatory Diseases Drug Forecasted Market Size by Application (US$ Million), 2027–2032
Table 31. Global Systemic Autoinflammatory Diseases Drug Revenue Market Share by Application (2027–2032)
Table 32. North America Systemic Autoinflammatory Diseases Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. North America Systemic Autoinflammatory Diseases Drug Market Size by Country (US$ Million), 2021–2026
Table 34. North America Systemic Autoinflammatory Diseases Drug Market Size by Country (US$ Million), 2027–2032
Table 35. Europe Systemic Autoinflammatory Diseases Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. Europe Systemic Autoinflammatory Diseases Drug Market Size by Country (US$ Million), 2021–2026
Table 37. Europe Systemic Autoinflammatory Diseases Drug Market Size by Country (US$ Million), 2027–2032
Table 38. Asia-Pacific Systemic Autoinflammatory Diseases Drug Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 39. Asia-Pacific Systemic Autoinflammatory Diseases Drug Market Size by Region (US$ Million), 2021–2026
Table 40. Asia-Pacific Systemic Autoinflammatory Diseases Drug Market Size by Region (US$ Million), 2027–2032
Table 41. Latin America Systemic Autoinflammatory Diseases Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Latin America Systemic Autoinflammatory Diseases Drug Market Size by Country (US$ Million), 2021–2026
Table 43. Latin America Systemic Autoinflammatory Diseases Drug Market Size by Country (US$ Million), 2027–2032
Table 44. Middle East & Africa Systemic Autoinflammatory Diseases Drug Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Middle East & Africa Systemic Autoinflammatory Diseases Drug Market Size by Country (US$ Million), 2021–2026
Table 46. Middle East & Africa Systemic Autoinflammatory Diseases Drug Market Size by Country (US$ Million), 2027–2032
Table 47. Novartis Company Details
Table 48. Novartis Business Overview
Table 49. Novartis Systemic Autoinflammatory Diseases Drug Product
Table 50. Novartis Revenue in Systemic Autoinflammatory Diseases Drug Business (US$ Million), 2021–2026
Table 51. Novartis Recent Development
Table 52. Abbvie Company Details
Table 53. Abbvie Business Overview
Table 54. Abbvie Systemic Autoinflammatory Diseases Drug Product
Table 55. Abbvie Revenue in Systemic Autoinflammatory Diseases Drug Business (US$ Million), 2021–2026
Table 56. Abbvie Recent Development
Table 57. Abbott Laboratories Company Details
Table 58. Abbott Laboratories Business Overview
Table 59. Abbott Laboratories Systemic Autoinflammatory Diseases Drug Product
Table 60. Abbott Laboratories Revenue in Systemic Autoinflammatory Diseases Drug Business (US$ Million), 2021–2026
Table 61. Abbott Laboratories Recent Development
Table 62. Regeneron Pharmaceuticals Company Details
Table 63. Regeneron Pharmaceuticals Business Overview
Table 64. Regeneron Pharmaceuticals Systemic Autoinflammatory Diseases Drug Product
Table 65. Regeneron Pharmaceuticals Revenue in Systemic Autoinflammatory Diseases Drug Business (US$ Million), 2021–2026
Table 66. Regeneron Pharmaceuticals Recent Development
Table 67. Swedish Orphan Biovitrum AB Company Details
Table 68. Swedish Orphan Biovitrum AB Business Overview
Table 69. Swedish Orphan Biovitrum AB Systemic Autoinflammatory Diseases Drug Product
Table 70. Swedish Orphan Biovitrum AB Revenue in Systemic Autoinflammatory Diseases Drug Business (US$ Million), 2021–2026
Table 71. Swedish Orphan Biovitrum AB Recent Development
Table 72. Pfizer, Inc. Company Details
Table 73. Pfizer, Inc. Business Overview
Table 74. Pfizer, Inc. Systemic Autoinflammatory Diseases Drug Product
Table 75. Pfizer, Inc. Revenue in Systemic Autoinflammatory Diseases Drug Business (US$ Million), 2021–2026
Table 76. Pfizer, Inc. Recent Development
Table 77. Bausch Health Company Details
Table 78. Bausch Health Business Overview
Table 79. Bausch Health Systemic Autoinflammatory Diseases Drug Product
Table 80. Bausch Health Revenue in Systemic Autoinflammatory Diseases Drug Business (US$ Million), 2021–2026
Table 81. Bausch Health Recent Development
Table 82. Mallinckrodt Company Details
Table 83. Mallinckrodt Business Overview
Table 84. Mallinckrodt Systemic Autoinflammatory Diseases Drug Product
Table 85. Mallinckrodt Revenue in Systemic Autoinflammatory Diseases Drug Business (US$ Million), 2021–2026
Table 86. Mallinckrodt Recent Development
Table 87. Johnson & Johnson Company Details
Table 88. Johnson & Johnson Business Overview
Table 89. Johnson & Johnson Systemic Autoinflammatory Diseases Drug Product
Table 90. Johnson & Johnson Revenue in Systemic Autoinflammatory Diseases Drug Business (US$ Million), 2021–2026
Table 91. Johnson & Johnson Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
Table 95. Authors List of This Report
List of Figures
Figure 1. Systemic Autoinflammatory Diseases Drug Picture
Figure 2. Global Systemic Autoinflammatory Diseases Drug Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Systemic Autoinflammatory Diseases Drug Market Share by Type: 2025 vs 2032
Figure 4. Injectables Features
Figure 5. Oral Features
Figure 6. Other Features
Figure 7. Global Systemic Autoinflammatory Diseases Drug Market Size by Application (US$ Million), 2021–2032
Figure 8. Global Systemic Autoinflammatory Diseases Drug Market Share by Application: 2025 vs 2032
Figure 9. Ulcerative Colitis Case Studies
Figure 10. Juvenile Rheumatoid Arthritis Case Studies
Figure 11. Psoriatic Arthritis Case Studies
Figure 12. Other Indications Case Studies
Figure 13. Systemic Autoinflammatory Diseases Drug Report Years Considered
Figure 14. Global Systemic Autoinflammatory Diseases Drug Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 15. Global Systemic Autoinflammatory Diseases Drug Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Systemic Autoinflammatory Diseases Drug Market Share by Region: 2025 vs 2032
Figure 17. Global Systemic Autoinflammatory Diseases Drug Market Share by Players in 2025
Figure 18. Global Systemic Autoinflammatory Diseases Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by Systemic Autoinflammatory Diseases Drug Revenue in 2025
Figure 20. North America Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. North America Systemic Autoinflammatory Diseases Drug Market Share by Country (2021–2032)
Figure 22. United States Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Canada Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Systemic Autoinflammatory Diseases Drug Market Share by Country (2021–2032)
Figure 26. Germany Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. France Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. U.K. Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Italy Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Russia Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Ireland Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Systemic Autoinflammatory Diseases Drug Market Share by Region (2021–2032)
Figure 34. China Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Japan Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. South Korea Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Southeast Asia Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. India Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Australia & New Zealand Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Systemic Autoinflammatory Diseases Drug Market Share by Country (2021–2032)
Figure 42. Mexico Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Brazil Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Systemic Autoinflammatory Diseases Drug Market Share by Country (2021–2032)
Figure 46. Israel Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Saudi Arabia Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. UAE Systemic Autoinflammatory Diseases Drug Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Novartis Revenue Growth Rate in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
Figure 50. Abbvie Revenue Growth Rate in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
Figure 51. Abbott Laboratories Revenue Growth Rate in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
Figure 52. Regeneron Pharmaceuticals Revenue Growth Rate in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
Figure 53. Swedish Orphan Biovitrum AB Revenue Growth Rate in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
Figure 54. Pfizer, Inc. Revenue Growth Rate in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
Figure 55. Bausch Health Revenue Growth Rate in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
Figure 56. Mallinckrodt Revenue Growth Rate in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
Figure 57. Johnson & Johnson Revenue Growth Rate in Systemic Autoinflammatory Diseases Drug Business (2021–2026)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
